Science | June 29, 2023

FDA Approves BioMarin’s Gene Therapy for a Genetic Bleeding Disorder

We’re thrilled to share that the U.S. Food and Drug Administration has approved our gene therapy for a genetic bleeding disorder. Developing the one-time therapy and bringing it over the finish line, first in Europe and now the United States, has been a global effort. Our teams have made unprecedented scientific, medical, manufacturing and regulatory […]

Our Company | April 17, 2023

A Message from the Chairman and CEO

Dear Stockholder of BioMarin: In 2022, BioMarin achieved record revenue and pivoted to GAAP profitability, making it a truly transformational year for the company and laying the foundation for long-term growth. The global launch of VOXZOGO for children with achondroplasia helped drive that revenue growth. We believe conditional European approval of our gene therapy for […]

Our Company | December 5, 2022

Enduring Purpose, Expanding Reach

As we reflect on the progress of the last quarter century, we take this opportunity to also look forward to what’s next for BioMarin. In our continued pursuit to maximize impact for patients, we continue to ask ourselves: what more can we do? The outcome of this ongoing self-assessment has helped bring clarity to how we can best deliver on our purpose – to transform lives through genetic discovery.